Bristol Myers Squibb Defies Patent Cliff: Blockbuster Sales of Opdivo and Eliquis Drive Raised Forecast
BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.
/ 1677 items
#XY↓
Moderna Explores Major Deal Options, Including Potential Buyout
Moderna is in discussions with large pharmaceutical companies about significant deals, including a possible buyout.
Cigna Warns of Profit Pressure as It Overhauls Pharmacy Benefits Model
Cigna Group expects margin pressure in pharmacy benefits over two years as it phases out drug rebates and renews major contracts with lower profit margins.
Sensei Biotherapeutics Halts Drug Development, Explores Strategic Options
Sensei Biotherapeutics discontinues solnerstotug development and begins strategic review including potential sale, merger, or wind-down to maximize shareholder value.
Cardinal Health Beats Expectations, Raises 2026 Profit Outlook on Strong Drug Sales
Cardinal Health increases annual profit forecast to $9.65-$9.85 per share after exceeding Q1 expectations, driven by specialty medicines and branded drug demand.
Eli Lilly Soars on Blockbuster Weight-Loss Drug Sales, Raises 2025 Outlook
Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.